Product Description
Betamethasone topical is used to treat the itching, redness, dryness, crusting, scaling, inflammation, and discomfort of various skin conditions, including psoriasis (a skin disease in which red, scaly patches form on some areas of the body) and eczema (a skin disease that causes the skin to be dry and itchy and to sometimes develop red, scaly rashes). Betamethasone is in a class of medications called corticosteroids. It works by activating natural substances in the skin to reduce swelling, redness, and itching.
Mechanisms of Action: GR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical,Intramuscular
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: LEO Pharma
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Belgium, China, Denmark, France, Germany, Italy, Mexico, Netherlands, New Zealand, Poland, Spain, Turkey, United States
Active Clinical Trial Count: 15
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Candidiasis|Pain Unspecified|Pigmentation Disorders|Psoriasis|Retinitis Pigmentosa|Rhinitis, Allergic
Phase 2: Fallopian Tube Cancer|Ovarian Cancer|Peritoneal Cancer|Sinusitis
Phase 1: Dermatitis, Atopic|Healthy Volunteers|Oncology Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| MGT-RPGR-022 | P3 |
Active, not recruiting |
Retinitis Pigmentosa |
2029-12-19 |
2025-05-02 |
Treatments |
|
| ZNâc3-005 | P2 |
Recruiting |
Peritoneal Cancer|Ovarian Cancer|Fallopian Tube Cancer |
2027-09-01 |
2025-05-02 |
Treatments |
|
| 21-01/ClotriBet-S | P3 |
Recruiting |
Candidiasis |
2025-12-01 |
2025-05-02 |
Treatments |
|
| PIPA - Dermavant | P3 |
Enrolling by invitation |
Pigmentation Disorders|Psoriasis |
2025-07-01 |
4% |
2024-08-21 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments |
| FESS | P2 |
Recruiting |
Sinusitis |
2025-06-01 |
12% |
2024-11-13 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
| DESCUBRA | P3 |
Recruiting |
Rhinitis, Allergic |
2025-05-11 |
41% |
2025-04-09 |
|
| 2006-7041-83/hah | P1 |
Not yet recruiting |
Oncology Unspecified|Healthy Volunteers |
2018-10-22 |
|||
| 2016-000407-84 | P3 |
Active, not recruiting |
Pain Unspecified |
2018-04-13 |
2022-03-13 |
Treatments |
|
| SIL-30953-III-23(1) | P3 |
Recruiting |
Unknown |
2026-12-31 |
39% |
2025-03-08 |
|
| RopiCloBet | P1 |
Completed |
Healthy Volunteers |
2025-02-20 |
69% |
2025-05-20 |
|
| 2020-004081-19 | P3 |
Active, not recruiting |
Psoriasis |
2023-12-22 |
|||
| CTR20222869 | P2 |
Completed |
Unknown |
2023-06-18 |
2025-06-01 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
| ACTRN12624000107527 | P1 |
Not yet recruiting |
Dermatitis, Atopic|Psoriasis |
None |
2024-08-29 |
Start Date|Treatments|Trial Status |
|
| ACTRN12624000621516 | P1 |
Not yet recruiting |
Dermatitis, Atopic|Psoriasis |
None |
2024-08-29 |
Start Date|Treatments|Trial Status |
|
| CTR20233982 | P3 |
Recruiting |
Unknown |
None |
2025-04-29 |
Patient Enrollment|Start Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
03/26/2025 |
News Article |
Public Advisory - Health Canada warns about unauthorized health products that may pose serious health risks |
|
03/07/2025 |
News Article |
Head-to-Head Preclinical Studies of SFA-002 as a Novel Psoriasis Treatment Presented at the 2025 American Academy of Dermatology Annual Meeting |
|
11/15/2024 |
News Article |
Endo Announces Agreement for Paladin Pharma to Commercialize Wynzora® Cream in Canada |
|
10/31/2024 |
News Article |
LEO Pharma Continues to Deliver Double-Digit Revenue Growth Backed by Strong Dermatology Sales |